ORAL PRESENTATION



Open Access

Next-generation LTR-specific Tre-recombinase targets a majority of HIV-1 isolates

Joachim Hauber^{1*}, Janet Karpinski², Ilona Hauber¹, Jan Chemnitz¹, Helga Hofmann-Sieber¹, Claus-Henning Nagel¹, Niklas Beschorner¹, Carola Schäfer¹, Frank Buchholz²

From International Symposium HIV and Emerging Infectious Diseases 2014 Marseille, France. 21-23 May 2013

Introduction

HIV-1 integrates into the host chromosome and persists as a provirus flanked by long terminal repeats (LTR). To date, treatment regimens primarily target the virus enzymes, virus attachment or virus-cell fusion, but not the integrated provirus. Thus, current antiretroviral therapies (i.e. cART) cannot eradicate HIV-1, a fact that highlights the urgency of pursuing new strategies to find a cure for HIV/AIDS.

Previously, we engineered an experimental LTR-specific recombinase (Tre-recombinase) that can effectively excise integrated HIV-1 proviral DNA from infected human cell cultures (Sarkar et al. 2007 Science 316:1912). Subsequently, we demonstrated highly significant antiviral activity of this HIV-1 subtype A-specific Tre in humanized mice (Hauber et al. 2013 PLOS pathogens 9:e1003587). Broad clinical application, however, requires availability of a tre-recombinase that recognizes a majority of clinical HIV-1 isolates.

Materials and methods

Here we report LTR target site identification as well as the engineering and functional analysis of a next-generation Tre-recombinase that recognizes the vast majority (e.g. >93% clade B and >80% clade A) of clinical HIV-1 isolates.

Results

It is shown that the HIV-1 LTR harbours a conserved region that may serve as a universal tre recognition site for provirus excision. In fact, targeting this site by nextgeneration tre-recombinase demonstrates pronounced antiviral activity in the absence of cellular toxicity.

¹Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

Full list of author information is available at the end of the article

Conclusion

The presented data suggest that next-generation Tre technology may be a valuable component of future antiretroviral therapies to reverse infection and thereby providing a cure for HIV/AIDS.

Authors' details

¹Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany. ²University of Technology Dresden, University Hospital and Medical Faculty Carl Gustav Carus, Department of Medical Systems Biology, Dresden, Germany.

Published: 23 May 2014

doi:10.1186/1471-2334-14-S2-O18 Cite this article as: Hauber *et al.*: Next-generation LTR-specific Trerecombinase targets a majority of HIV-1 isolates. *BMC Infectious Diseases* 2014 14(Suppl 2):O18.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit



© 2014 Hauber et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.